Representative experiment showing synergistic cytotoxic activity of bendamustine when combined with doxorubicin and bortezomib in H929 cells. B, 15μg/ml bendamustine; D, 0.03μg/ml doxorubicin; V, 2.5nmol/L bortezomib; B+D, 15μg/ml bendamustine and 0.03μg/ml doxorubicin; B+V, 15μg/ml bendamustine and 2.5nmol/L bortezomib; D+V, 0.03μg/ml doxorubicin and 2.5nmol/L bortezomib; B+D+V, the combination of 15μg/ml bendamustine with 0.03μg/ml doxorubicin and 2.5nmol/L bortezomib. Synergy of the drug combination was defined when the measured cell survival was lower than the product of the effect of each single drug.